Table 2 Gene ontology (GO) categories identified using IPA
Gene ontology category | P-value range | Number of genes |
|---|---|---|
Inflammatory response | 1.66 × 10-11 - 1.64 × 10-2 | 241 |
Cellular development | 8.95 × 10-10 - 1.57 × 10-2 | 308 |
Cellular growth and proliferation | 1.65 × 10-9 - 1.57 × 10-2 | 333 |
Haematological system development and function | 1.65 × 10-9 - 1.64 × 10-2 | 279 |
Haematopoiesis | 2.60 × 10-8 - 1.57 × 10-2 | 173 |
Tissue morphology | 1.78 × 10-7 - 1.19 × 10-2 | 114 |
Cellular function and maintenance | 5.44 × 10-7 - 1.65 ×10-2 | 138 |
Cell death | 9.57 × 10-7 - 1.60 × 10-2 | 419 |
Cell-mediated immune response | 1.06 × 10-6 - 1.25 × 10-2 | 109 |
Connective tissue disorders | 1.72 × 10-6 - 5.94 × 10-3 | 234 |
Immunological disease | 1.72 × 10-6 - 1.57 × 10-2 | 344 |
Inflammatory disease | 1.72 × 10-6 - 1.28 × 10-2 | 364 |
Skeletal and muscular disorders | 1.72 × 10-6 - 1.22 × 10-2 | 235 |
Infectious disease | 1.82 × 10-6 - 1.17 × 10-2 | 223 |
Cell-to-cell signalling and interaction | 8.33 × 10-6 - 1.64 × 10-2 | 210 |
Dermatological diseases and conditions | 1.04 × 10-5 - 1.57 × 10-2 | 107 |
Free radical scavenging | 1.23 × 10-5 - 1.23 × 10-5 | 14 |
Molecular transport | 1.23 × 10-5 - 7.43 × 10-3 | 86 |
Cell signalling | 2.40 × 10-5 - 7.21 × 10-5 | 133 |
Respiratory disease | 2.86 × 10-5 - 1.24 × 10-2 | 109 |
Cellular compromise | 3.09 × 10-5 - 1.57 × 10-2 | 41 |
Genetic disorder | 3.39 × 10-5 - 1.64 × 10-2 | 104 |
Immune cell trafficking | 3.51 × 10-5 - 1.64 × 10-2 | 163 |
Humoral immune response | 5.08 × 10-5 - 1.19 × 10-2 | 78 |
Organismal injury and abnormalities | 9.51 × 10-5 - 1.05 × 10-2 | 81 |
Tissue development | 1.19 × 10-4 - 1.05 × 10-2 | 108 |
Haematological disease | 1.78 × 10-4 - 1.35 × 10-2 | 162 |
Gastrointestinal disease | 1.88 × 10-4 - 5.51 × 10-3 | 42 |
Hepatic system disease | 1.88 × 10-4 - 1.64 × 10-2 | 89 |
Lymphoid tissue structure and development | 1.94 × 10-4 - 5.94 × 10-3 | 5 |
Antigen presentation | 3.42 × 10-4 -1.64 × 10-2 | 83 |
Cellular movement | 3.58 × 10-4 - 1.63 × 10-2 | 157 |
Vitamin and mineral metabolism | 3.59 × 10-4 - 7.21 × 10-3 | 74 |
Antimicrobial response | 3.92 × 10-4 - 1.28 × 10-2 | 32 |
Hypersensitivity response | 5.86 × 10-4 - 8.60 × 10-3 | 31 |
Infection mechanism | 9.89 × 10-4 - 1.57 × 10-2 | 39 |
Gene expression | 1.07 × 10-3 - 1.57 × 10-2 | 254 |
Hair and skin development and function | 1.23 × 10-3 - 1.57 × 10-2 | 22 |
Post-translational modification | 2.27 × 10-3 - 9.78 × 10-3 | 84 |
Cancer | 2.51 × 10-3 - 1.57 × 10-2 | 385 |
Endocrine system development and function | 2.65 × 10-3 - 2.65 × 10-3 | 21 |
Carbohydrate metabolism | 3.77 × 10-3 - 3.77 × 10-3 | 6 |
Cell morphology | 3.77 × 10-3 - 1.28 × 10-2 | 23 |
Lipid metabolism | 3.77 × 10-3 - 7.43 × 10-3 | 17 |
Neurological disease | 3.77 × 10-3 - 1.47 × 10-2 | 49 |
Small molecule biochemistry | 3.77 × 10-3 - 7.43 × 10-3 | 23 |
Metabolic disease | 3.91 × 10-3 - 3.91 × 10-3 | 7 |
Embryonic development | 4.59 × 10-3 - 1.57 × 10-2 | 21 |
Nervous system development and function | 4.59 × 10-5 - 1.18 × 10-2 | 8 |
Reproductive system disease | 5.84 × 10-3 - 7.54 × 10-3 | 79 |
Cell cycle | 5.94 × 10-3 - 1.18 × 10-2 | 20 |
Endocrine system disorders | 5.94 × 10-3 - 5.94 × 10-3 | 3 |
Opthalmic disease | 5.94 × 10-3 - 6.60 × 10-3 | 7 |
RNA post-transcriptional modification | 6.04 × 10-3 - 6.04 × 10-3 | 13 |
Cardiovascular system development and function | 6.68 × 10-3 - 1.30 ×10-2 | 19 |
Cell assembly and modification | 6.68 × 10-3 - 1.28 × 10-2 | 14 |
Organ development | 6.68 × 10-3 - 1.19 × 10-2 | 6 |
Renal and urological system development and function | 1.18 × 10-2 - 1.30 × 10-2 | 11 |
Reproductive system development and function | 1.18 × 10-2 - 1.18 × 10-2 | 4 |